In order to target resources and drugs to reach trachoma elimination targets by the year 2020, data on the burden of disease are required. Using prevalence data in African countries derived from the Global Atlas of Trachoma (GAT), the distribution of trachoma continues to be focused in East and West ... Sub-Saharan Africa, North Africa and a few endemic countries in Central Sub-Saharan Africa. Currently, 129.4 million people are estimated to live in areas that are confirmed to be trachoma endemic and 98 million are known to require access to the SAFE strategy. The maps and information presented in this work highlight the GAT as important open-access planning and advocacy tool for efforts to finalize trachoma mapping and assist national programmes in planning interventions. more

Surveys are needed to guide trachoma control efforts in Mozambique, with WHO guidelines for intervention based on the prevalence of trachomatous inflammation–follicular (TF) in children aged 1–9 years and the prevalence of trichiasis in adults aged 15 years and above. We conducted surveys to com ... plete the map of trachoma prevalence in Mozambique, concluding that it still represents a significant public health problem in many areas of Mozambique. more

Since 1996, trachoma has been targeted for elimination as a public health problem worldwide. The active trachoma criterion for national elimination as a public health problem is a TF1–9 < 5%, sustained for at least two years in the absence of antibiotic mass drug administration (MDA), in each formerly endemic EU. Usi ... ng A, F and E, health ministries and their partners have made considerable progress towards achieving this criterion in formerly endemic EUs worldwide. In 2002, an estimated 1517 million people lived in EUs in which EU-wide implementation of the A, F and E components of SAFE were thought to be needed for the purposes of global elimination of trachoma as a public health problem; by June 2021, that number had fallen to 136.2 million, a 91% reduction. Approximately 85% of the 136.2 million people living in EUs needing A, F and E in June 2021 were in WHO’s African Region. more

The World Health Organization (WHO) endorses the use of population-based prevalence surveys for estimating the prevalence of trachoma. In general, the prevalence of TF in children aged 1–9 years and the prevalence of TT in adults aged ≥ 15 years are measured at the same time in any district bein ... g surveyed. This was the approach of the Global Trachoma Mapping Project, which undertook baseline surveys in > 1500 districts worldwide in order to provide the data required to start interventions where needed.
The survey design recommended by WHO is a two-stage cluster random sample survey, which uses probability proportional to size sampling to select 20–30 villages, and random, systematic or quasi-random sampling to select 25–30 households in each of those villages. In most surveys, everyone aged ≥ 1 year living in selected households is examined. more

The World Health Organization (WHO) endorses the use of population-based prevalence surveys for estimating the prevalence of trachoma. In general, the prevalence of TF in children aged 1–9 years and the prevalence of TT in adults aged ≥ 15 years are measured at the same time in any district bein ... g surveyed. This was the approach of the Global Trachoma Mapping Project, which undertook baseline surveys in > 1500 districts worldwide in order to provide the data required to start interventions where needed.
The survey design recommended by WHO is a two-stage cluster random sample survey, which uses probability proportional to size sampling to select 20–30 villages, and random, systematic or quasi-random sampling to select 25–30 households in each of those villages. In most surveys, everyone aged ≥ 1 year living in selected households is examined. more

The Fifty-first World Health Assembly adopted resolution WHA51.11 in 1998, which targets the global elimination of trachoma as a public health problem by 2020 (1). The strategy recommended to achieve that goal is encapsulated by the acronym “SAFE”, which represents: Surgery for individuals wi ... th trachomatous trichiasis (TT; the late blinding stage of trachoma); and Antibiotics, Facial cleanliness and Environmental improvement (2). The A, F and E interventions are delivered to entire districts in which active (inflammatory) trachoma is common in order to treat ocular infection with Chlamydia trachomatis, the causative organism of trachoma, and sustainably reduce its transmission. more

En 1998, la Cinquante-et-Unième Assemblée mondiale de la Santé a adopté la résolution WHA51.11 qui vise l’élimination mondiale du trachome en tant que problème de santé publique à l’horizon 2020 (1). La stratégie recommandée pour atteindre cet objectif est récapitulée dans le sig ... le « CHANCE » qui signifie CHirurgie pour les personnes atteintes de trichiasis trachomateux (TT – le dernier stade cécitant du trachome) ; Antibiothérapie, Nettoyage du visage et Changements Environnementaux (2). Les interventions relatives aux volets A, N et CE sont menées dans des districts entiers dans lesquels les cas de trachome évolutif (inflammatoire) sont courants, dans le but de traiter les infections oculaires dues à Chlamydia trachomatis, l’agent pathogène à l’origine du trachome, et de réduire durablement sa transmission. more

La quincuagésima primera Asamblea de la Salud Mundial aprobó la resolución WHA51.11 en 1998, que busca la eliminación mundial del tracoma como problema de salud pública para el 2020 (1). La estrategia recomendada para lograr ese objetivo está encapsulada por las siglas "SAFE", que represent ... a: La cirugía para los individuos con triquiasis tracomatosa (TT; la última etapa que causa ceguera por tracoma); y Antibióticos, Limpieza Facial y Mejoramiento ambiental (2). Las intervenciones A, F y E se llevan a distritos enteros en los que el tracoma activo (inflamatorio) es común para tratar la infección ocular causada por Chlamydia trachomatis, el agente causal del tracoma y reduce de manera sustentable su transmisión. more